Outlook Therapeutics (OTLK)

• Market cap: $183M
• 1 day: -6.1%
• 5 days: -31.23%
• 1 month: -38.58%
• 3 months: 290.64%
• 6 months: 121.95%
• Year to date: 47.97%
• 1 year: -50.17%
• 5 years: -97.84%
• 10 years: -99.8%
• Sector: Healthcare
• Industry: Biotechnology

About: Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Employees: 17